Menu

Sign in

Sign in

Contact us

Homepage > Company > Media > Pharma News > 2018

Pharma News, 2018

A reversal of fortunes: Judge voids order Gilead must pay $2.5B to Merck over a patent dispute

A reversal of fortunes: Judge voids order Gilead must pay $2.5B to Merck over a patent dispute

In a reversal of fortunes, a federal judge overturned a jury verdict ordering Gilead Sciences (GILD) to pay $2.

Roche to buy Flatiron Health for $1.9 billion to expand cancer care portfolio

Roche to buy Flatiron Health for $1.9 billion to expand cancer care portfolio

(Reuters) - Swiss drugmaker Roche Holding AG (ROG.

Camber launches generic Celexa oral solution

Camber launches generic Celexa oral solution

Camber Pharmaceuticals has added to its portfolio of oral generics.

FDA Approves Apalutamide for Nonmetastatic Prostate Cancer

FDA Approves Apalutamide for Nonmetastatic Prostate Cancer

The US Food and Drug Administration (FDA) today approved apalutamide (Erleada, Janssen) for the treatment of patients with nonmetastatic prostate cancer who are at high risk for diseas...

Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Merck KGaA, Darmstadt, Germany, and Pfizer Inc.

Camber’s generic Viread launches

Camber’s generic Viread launches

Camber Pharmaceuticals has launched its generic Viread (tenofovir disoproxil fumarate) tablets.

Merck scraps another late-stage Alzheimer's drug study

Merck scraps another late-stage Alzheimer's drug study

NEW YORK (Reuters) - Merck & Co Inc on Tuesday said it will end another late-stage trial of an Alzheimer’s drug because it was unlikely to work, adding to the pile-up of failures to find...

Japanese Company Claims Experimental Drug Kills Flu Virus in a Single Day

Japanese Company Claims Experimental Drug Kills Flu Virus in a Single Day

In the midst of one of the worst flu seasons in several years, a Japanese pharmaceutical company says it has an experimental drug that could make next winter a lot less sickly – not to mention safer...

Tetraphase's antibiotic fails late-stage study, shares plummet

Tetraphase's antibiotic fails late-stage study, shares plummet

(Reuters) - Tetraphase Pharmaceuticals Inc said on Tuesday its lead experimental antibiotic to treat serious infections did not meet the main goals in a late-stage study, sending its shares pl...

Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema

Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema

Roivant and Poxel Announce Strategic Agreement for Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries Worldwide

Roivant and Poxel Announce Strategic Agreement for Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries Worldwide

BASEL, Switzerland & LYON, France--(BUSINESS WIRE)-- Roivant Sciences, a global healthcare company focused on realizing the full value of promising biomedical research, and POXEL SA ...

FDA Approves SYMDEKO (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene

FDA Approves SYMDEKO (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq.

59 60 61 626364 65 66 67

0 items in Cart

Cart Subtotal:

You will be able to Pay Online or Request a Quote